DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Acute Heart Failure – U.S. Current Treatment

    Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and morbidity and these rates have not significantly changed in the recent years. None of the currently approved AHF therapies have been demonstrated to improve clinical outcomes; therefore, the main focus of current treatment of AHF remains symptomatic relief. Here we show how AHF is currently being treated and what drives the choice of pharmacotherapy for AHF patients. We reveal how and when AHF agents are being used, from the initiation of therapy, typically with loop diuretics, through to further lines of treatment.

    Questions answered in this report:

    • Which drugs are most-commonly used to treat AHF patients and how does this change according to patient characteristics?
    • What are the typical treatment patterns for AHF patients? Which drugs are prescribed in each line of treatment, and what triggers the switch to the next line of treatment?
    • Do treatment approaches differ between patients with acutely decompensated HF and de novo AHF?
    • What are the cardiologist-reported factors determining current prescribing patterns for AHF and recent/anticipated changes?